A footnote in the fine print? *What* fine print are you referring to?
The above is the kind of delusional rant one often sees on Yahoo and on this board in particular. A few years ago, people here were posting that SGP was lying to investors about the phase-2 Victrelis data. Now, VRUS has supplanted MRK/SGP as the perceived archenemy, but the mindset remains the same, evidently.
SGP WAS fudging on Victrelis trial data. Right now VRUS is less than complete with the data they are releasing and it brings about suspicion. It may well turn out that VRVS has just what they claim to have. They are riding the wave of success, and VRTX has taken a big hit as a result. With more complete data VRUS could be the one taking the hit and VRTX could regain darling status. We'll just have to wait and see. At the very least, I'll give VRUS credit for making a great stride in the science of treating Hep C.